CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.

Oncotarget · 2014 · PMC4171647 · PMID 25156567

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Additionally, in breast cancer CDK4/6 inhibitors have demonstrated highly significant activity in combination with endocrine agents [ 46 - 50 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.